A reference companion to "I Made Money Today on Psychedelics. I'm Not Celebrating."
Addendum: The Heart Protocol — Jargon, Misnomers & What the Terms Actually Mean
Why This Addendum Exists
The term "Heart Protocol" circulated widely after Tina Sodhi's death as though it named a coherent, established therapeutic modality. It did not. It named a brand — ceremony language applied to an unmonitored, unstudied, multi-compound drug administration in a heat environment.
This addendum dissects the jargon. Every term Lee used — protocol, ceremony, stacking, psychedelic, heart-opening — carries clinical weight in legitimate contexts and zero clinical infrastructure when stripped of that context. Understanding the difference is not academic. It is the difference between a field that earns trust and one that spends it.
A Note on Alexander Shulgin
Before dissecting what went wrong, it is worth acknowledging who got it right.
Alexander Shulgin (1925–2014) was the chemist who re-synthesized MDMA in 1976, recognized its therapeutic potential, and introduced it to psychotherapists including Leo Zeff. His two landmark volumes — PiHKAL (Phenethylamines I Have Known and Loved) and TiHKAL (Tryptamines I Have Known and Loved), co-authored with his wife Ann — documented the synthesis, dosing, and subjective effects of hundreds of psychoactive compounds with a rigor, honesty, and ethical seriousness that shames most of what followed.
Shulgin did not brand his work. He documented it. He warned about contraindications. He argued for careful, intentional use under qualified supervision. He understood that MDMA was a tool of extraordinary delicacy — not a ceremony ingredient to be stacked with ketamine and DMT and administered in a rooftop sauna.
The field owes him its foundational vocabulary. The least it can do is honor the precision with which he used it.
What "Protocol" Actually Means
In legitimate clinical practice, a protocol is a documented, peer-reviewed, IRB-approved procedural standard. It specifies:
- Fixed dosages with defined titration ranges
- Compound selection rationale tied to specific clinical indication
- Contraindication screening requirements (cardiac, hepatic, psychiatric, pharmacological)
- Monitoring requirements during administration
- Rescue procedures and stop criteria
- Integration support structure post-session
A published example: the Roots to Thrive ketamine-assisted therapy model delivers three structured ketamine sessions embedded in a 12-week Community of Practice, co-facilitated by a multidisciplinary team including healthcare providers, therapists, and somatic energy practitioners. That is a protocol.
What Lee called the "Heart Protocol" had none of this. The word "protocol" was branding — borrowed legitimacy. White coat language placed on a ceremony with no clinical infrastructure behind it.
The Three Compounds
MDMA, ketamine, and DMT operate through entirely different receptor systems, with different risk profiles, different durations, and radically different thermoregulatory consequences. Treating them as interchangeable or additively therapeutic is pharmacologically illiterate. Shulgin spent decades making precisely this point — that each compound deserves its own careful study, not casual combination.
| Compound | Category | Primary Mechanism | Duration | Legal Status | Evidence (Solo) | Stacking Risk |
|---|---|---|---|---|---|---|
| MDMA | Entactogen / Stimulant | Serotonin + dopamine + oxytocin flood; NOT 5-HT2A agonism | 4–6 hours | Schedule I; research only | Phase 3 PTSD trials (MAPS/Lykos); FDA CRL 2024 | CRITICAL — hyperthermia + serotonin syndrome amplified by co-administration |
| Ketamine | Dissociative Anesthetic | NMDA glutamate receptor blockade; NOT a classic psychedelic | 30–90 min | Schedule III; FDA-approved (Spravato) | Decades of clinical evidence; EMA + FDA approved for depression | HIGH — CNS depression compounded; thermoregulation further impaired |
| DMT (N,N) | Classic Psychedelic | 5-HT2A serotonin receptor agonist — the only true classic in this stack | 15–30 min smoked; 4–6 hr as ayahuasca | Schedule I; research only | Observational + early trials; no approved product | CRITICAL — serotonin syndrome risk with MDMA is documented and severe |
Eight Misnomers
| Term Used | The Myth | What It Actually Means | Why It Matters |
|---|---|---|---|
| Heart Protocol | A named modality with established methodology | A brand name. No published protocol, no IRB, no dosing standard, no monitoring criteria. | The word "protocol" implies institutional rigor. Borrowing it for an unvalidated ceremony is deception by nomenclature. |
| Psychedelic (all three) | MDMA + ketamine + DMT are all "psychedelics" and can be safely combined | Only DMT is a classic psychedelic (5-HT2A agonist). MDMA is an entactogen. Ketamine is a dissociative anesthetic. Three different receptor systems. | Calling all three "psychedelics" obscures mechanistic incompatibility. Different systems mean different risks and different pharmacological interactions. |
| Stacking | Combining compounds amplifies healing synergistically | Polypharmacy. No peer-reviewed evidence supports simultaneous MDMA + ketamine + DMT administration outside a controlled trial. | "Stacking" is borrowed from biohacking supplement culture. Applied to Schedule I/III controlled substances in a heat environment, it is a mechanism of death. |
| Ceremony | Ceremony is a safety container that confers protection | Ceremony is a meaning-making and intention-setting structure. It has no pharmacological safety function. | Framing indigenous ceremonial practice as a substitute for clinical monitoring is appropriation weaponized into a liability shield. |
| Heart-opening | MDMA creates cardiac and emotional opening — a healing modality | MDMA floods serotonin, dopamine, and oxytocin creating emotional openness. It also generates heat, causes vasoconstriction, and impairs thermoregulation. | "Heart-opening" is a marketing frame that omits the mechanism. In a sauna, MDMA-induced thermal dysregulation is lethal. |
| Psychedelic-Assisted Therapy | A defined, regulated treatment category | There are no standard definitions of what constitutes a psychotherapeutic intervention within a psychedelic-based treatment. The regulatory vacuum is real. | Anyone can call anything "psychedelic-assisted therapy." Lee did. No enforced nomenclature standard currently exists. |
| Elder / Facilitator | A title conveying ceremonial authority and competency | A self-assigned role with no credentialing standard, no training requirement, and no regulatory oversight in most jurisdictions. | Lee described himself as "a licensed medical doctor and an elder of the Eternal Life Tribe." Both titles obscured the absence of clinical protocol. |
| Integration | Post-session psychological processing support | In legitimate psychedelic-assisted practice, integration is structured therapeutic follow-up — typically 3–12 sessions with a qualified therapist. | Used loosely, "integration" often means a group share circle. The clinical definition requires qualified therapists and a defined session structure. |
The Mechanism Nobody Is Naming: Serotonin Syndrome
The combination of MDMA and DMT represents a textbook serotonin syndrome pathway that is neither obscure nor contested:
- MDMA floods serotonin release massively — it is the primary mechanism of action
- DMT agonizes serotonin 5-HT2A receptors directly
- Combined, they hit serotonin release, reuptake inhibition, and receptor agonism simultaneously
- Ketamine, added to this stack, compounds CNS depression and further impairs homeostatic regulation
Serotonin syndrome is characterized by cognitive dysfunction, autonomic instability, neuromuscular dysfunction, and hyperthermia. MDMA activates mechanisms that both conserve and generate heat while simultaneously causing peripheral vasoconstriction — closing the skin's heat-release valve. In a rooftop sauna, this was inevitable.
This is foundational pharmacology that any board-certified psychiatrist is required to know. Shulgin documented the thermal risks of MDMA in PiHKAL. The peer-reviewed literature has confirmed it since the 1990s. There is no universe in which ignorance is a defense.
What Legitimate Psychedelic Research Actually Looks Like
The organizations doing this work responsibly share common attributes that Lee's ceremony violated entirely.
MAPS (Multidisciplinary Association for Psychedelic Studies) — Founded by Rick Doblin, Ph.D. in 1986. MAPS has spent four decades funding and conducting the most rigorous clinical research on psychedelic medicines in the world. Their Phase 3 MDMA-assisted therapy trials for PTSD defined what a real protocol looks like: screened participants, trained therapists, monitored sessions, defined dosing, and structured integration. The FDA's 2024 Complete Response Letter was a setback, not a repudiation. In April 2026, a new Executive Order directed federal agencies to expand research and accelerate regulatory approval for psychedelic therapies. MAPS is 40 years in and still building. Now led by Co-Executive Directors Betty Aldworth and Ismail Lourido Ali, JD, with Rick Doblin serving as Founder and President.
Radicle Science — Co-founded and led by Dr. Jeff Chen, MD/MBA. Runs large-scale evidence-based trials for natural products under rigorous statistical methodology. Every claim is pre-registered, every outcome independently validated. Nearly 100 clinical trials completed. No compound is administered without documented safety parameters.
Wake Network — Co-founded and led by Nick Murray. Advancing psilocybin retreat clinical immersions grounded in science. Jamaica's largest psilocybin mushroom cultivation facility. Screening protocols, trained facilitators with defined credentialing pathways, and post-session integration support are built into the model structure.
AtaiBeckley (formerly Beckley Psytech, acquired by atai Life Sciences November 2025; now publicly traded Nasdaq: ATAI) — Led by CEO Dr. Srinivas Rao. Co-founder Cosmo Feilding Mellen now serves on the board. Clinical-stage biotech developing regulated psychedelic medicines for neurological and psychiatric conditions. Pipeline includes BPL-003 (5-MeO-DMT nasal spray) — Phase 3-ready for treatment-resistant depression — plus VLS-01 (DMT buccal film) and EMP-01 (R-MDMA) in Phase 2. IND filings, FDA interaction, $150M raised. This is the institutional rigor that earns the word "protocol."
TRIPP — Co-founded and led by Nanea Reeves. Recognized by TIME as a Best Invention for its XR-based mental wellness platform. Technology-mediated altered states with defined safety parameters, no Schedule I compounds, and clinical partnership structures. 10 million+ sessions delivered. Clinical studies underway in depression, anxiety, and substance use disorder.
MycoMedica Life Sciences — Co-founded by legendary mycologist Paul Stamets, whose work has defined modern understanding of psilocybin mushrooms. $60M raised. Clinical trials underway in PMDD, OCD, and opioid use disorder. Product claims tied to published research and composition patents, not ceremony branding. Stamets himself holds three psilocybin patents and six published books on fungi.
What these organizations share — defined terms, published evidence, safety infrastructure, and a refusal to stack compounds outside monitored trial settings — is precisely what the "Heart Protocol" lacked entirely. Shulgin would have recognized all of them. He would not have recognized what happened in Miami Beach.
Why ImpactSoul Is Building the Answer
The Psychedelic Readiness Index exists precisely because the nomenclature vacuum is the attack surface. When no one agrees on what "protocol," "ceremony," "assisted," or even "psychedelic" means, bad actors fill the gap with marketing.
ImpactSoul's scoring framework for consciousness-aligned capital evaluates organizations along six dimensions that directly address the failures in the Lee case:
- Clinical rigor — Is compound selection evidence-based? Are interactions screened?
- Safety infrastructure — What monitoring exists during administration? What is the stop protocol?
- Credentialing — What qualifies a facilitator? Is there a defined standard?
- Integration — Is post-session support structured and therapeutically supervised?
- Transparency — Are claims pre-registered? Are outcomes independently validated?
- Regulatory posture — Is the organization working toward approved pathways, not around them?
The "Heart Protocol" scored zero on every dimension. That is not a coincidence. It is the predictable outcome of a field without enforced standards — and the precise reason those standards matter.
Glossary
5-HT2A Receptor — A serotonin receptor subtype that is the primary target of classic psychedelics (psilocybin, LSD, DMT). Agonism here produces perceptual alteration, neuroplasticity, and the characteristic psychedelic experience. MDMA does not primarily act here.
Classic Psychedelic — A compound that produces altered consciousness primarily through 5-HT2A serotonin receptor agonism. Includes psilocybin, LSD, DMT, mescaline. Does NOT include MDMA or ketamine.
Dissociative Anesthetic — A compound that produces dissociation, analgesia, and amnesia through NMDA glutamate receptor antagonism. Ketamine is the primary clinical example.
Entactogen — A term coined by Alexander Shulgin to describe compounds that create emotional openness, empathy, and interpersonal connection through monoamine flooding. MDMA is the primary example. It is not a classic psychedelic.
Exertional Hyperpyrexia — Life-threatening overheating caused by the combination of a warm environment and a drug that impairs thermoregulation. The mechanism that killed Tina Sodhi.
Integration (clinical definition) — Structured post-session therapeutic support, typically 3–12 supervised sessions with a qualified therapist, designed to metabolize and contextualize an altered-state experience.
IRB — Institutional Review Board. An independent ethics committee that reviews and approves research protocols involving human subjects. No IRB ever reviewed the "Heart Protocol."
MAPS — Multidisciplinary Association for Psychedelic Studies. Founded 1986 by Rick Doblin, Ph.D. The organization responsible for the most rigorous clinical trials of psychedelic medicines conducted to date. maps.org
NMDA Receptor — N-methyl-D-aspartate receptor. A glutamate receptor subtype blocked by ketamine. Entirely distinct from the serotonin receptors targeted by classic psychedelics.
PiHKAL / TiHKAL — Phenethylamines I Have Known and Loved / Tryptamines I Have Known and Loved. Alexander Shulgin's two-volume pharmacological and autobiographical record. The foundational texts of modern psychedelic chemistry. Still in print. Required reading for anyone who calls themselves a practitioner.
Protocol (clinical definition) — A documented, peer-reviewed procedural standard specifying dosing, contraindication screening, monitoring, rescue procedures, and integration structure. Not a brand name.
Serotonin Syndrome — A potentially fatal drug reaction caused by excess serotonergic activity, characterized by hyperthermia, autonomic instability, and neuromuscular dysfunction. Risk is substantially elevated by MDMA + DMT co-administration.
Set and Setting — The psychological mindset (set) and physical environment (setting) of a psychedelic experience. A real determinant of outcome — but not a pharmacological safety mechanism.
Shulgin, Alexander (1925–2014) — Chemist, pharmacologist, author. Re-synthesized MDMA in 1976 and recognized its therapeutic potential. Coined the term entactogen. Authored PiHKAL and TiHKAL. The intellectual godfather of the field — and a man who never confused branding with science.
Stacking / Polypharmacy — The simultaneous administration of multiple psychoactive compounds. No peer-reviewed evidence supports the specific stack used in the Lee case (MDMA + ketamine + DMT).
Tony Greenberg — Founder, ImpactSoul · CEO, RampRate · Author, boy in the human · Speaker alongside Ray Kurzweil, 2010
Tony Greenberg — Founder, ImpactSoul · CEO, RampRate · Author, boy in the human · Speaker alongside Ray Kurzweil, 2010
